Eaton Vance Management Supernus Pharmaceuticals, Inc. Transaction History

Eaton Vance Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $66,000 - $76,163	-2,315 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $1,371 - $1,779	52 Added 2.3%	2,315 $0
Q3 2021 Nov 15, 2021	SELL	$23.54 - $31.39 $4,190 - $5,587	-178 Reduced 7.29%	2,263 $0
Q2 2021 Aug 16, 2021	BUY	$26.72 - $33.19 $53,894 - $66,944	2,017 Added 475.71%	2,441 $75,000
Q1 2021 May 17, 2021	BUY	$24.15 - $31.45 $10,239 - $13,334	424 New	424 $11,000

281

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.95B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

Stay updated on Eaton Vance Management with notifications on news.